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Abstract  
 
It is well established that immunosurveillance is active in the CNS and plays a key role in 
several CNS disorders but the exact role of immune cells remains elusive.  Thus, in the 
present study we investigated whether lymphocytes are protective / detrimental in in vitro 
models of excitotoxicty.  Kainate (KA)-induced neuronal death was significantly reduced 
following exposure to mixed lymphocytes or purified T lymphocytes containing either 
activated or non-activated T-lymphocytes.  Conditioned media from lymphocyte 
preparations, but not boiled conditioned media, was protective against KA-induced toxicity 
indicating soluble mediators underlie the observed neuroprotection with cytokine arrays 
indicating IL-16 as the likely candidate. A role for astrocytes was established as the 
neuroprotection was abolished in the presence of the glial toxin, fluoroacetate.   Furthermore, 
lymphocytes inhibited p38 MAPK and ERK signalling pathways with pharmacological 
inhibition of these pathways mimicking the protective effect of lymphocytes.  Similarly, 
lymphocytes were neuroprotective against oxygen-glucose deprivation (OGD)-induced cell 
death with the inhibition of p38 MAPK and ERK signalling pathways involved. These data 
indicate that lymphocytes are neuroprotective under our experimental conditions and we 
suggest that astrocytic activation and inhibition of MAPK signalling cascades are involved 
but further studies are required to investigate whether similar mechanisms underlie the 
actions of lymphocytes in in vivo experimental models of disease.    
  
Keywords: astrocytes, lymphocytes, MAP kinases, neuroinflammation, neuroprotection, T 
cells.  
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1. Introduction 
Within the brain, there is an absence of lymphatic vessels and the classical major 
histocompatibility complex (MHC) molecules, leading to the suggestion that the brain shows 
limited immune surveillance or is an immunologically privileged area (Becher et al., 2006; 
Engelhardt, 2006). However, it is evident that the brain is not µLPPXQH-SULYLOHJHG¶ as it is 
now well established that immune cells can cross the blood-brain barrier (BBB) (Hickey, 
1999, Becher et al., 2006) and extensive studies have suggested that immune cells can play 
both detrimental or protective roles in central nervous system (CNS) function (for reviews 
see Cohen and Schwartz, 1999; Schwartz, 2005; Dittel, 2008).  
 
It has been proposed that activated T cells cross the BBB irrespective of antigen specificity 
and, following recognition of specific antigens by antigen presenting cells (APCs) including 
astrocytes, dendritic cells and microglia, remain in the CNS to initiate an inflammatory 
reaction (Hickey et al., 1991; Liblau et al., 2013). Within the CNS, T cells have the capacity 
to proliferate, interact with resident APCs and produce cytokines that exacerbate the 
inflammatory response, which may contribute to the neurological symptoms observed in 
certain CNS diseases including amyotrophic lateral sclerosis and multiple sclerosis 
(Ponomarev et al., 2004, 2007; Batoulis et al., 2011). Indeed, aseptic cerebral injury is 
reduced in T cell-deficient recombinase activating gene knock out (RAG -/-) mice whereas 
cerebral injury is exacerbated when activated CD4+ T cells are re-introduced into these mice 
(Fee et al., 2003).  In contrast to the general concept that T cell infiltration is detrimental to 
the CNS, T cells and B cells can also contribute to the maintenance of normal physiology 
(Cohen and Schwartz, 1999; Kipnis et al., 2004; Ziv et al., 2006; Wolf et al., 2009) and there 
is increasing evidence that T cells may be beneficial following CNS trauma (Cohen and 
Schwartz, 1999; Schwartz, 2005). An example of this is the impaired survival of facial motor 
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neurons in severe combined immunodeficient (SCID) mice after experimental facial nerve 
axotomy, which is restored following transfer of wild-type splenocytes (a mixture of T and B 
cells) (Serpe et al., 1999). Moreover, adoptive transfer of T cells reactive to Cop-1 following 
injury also increases the number of surviving neurons (Kipnis et al., 2000). The underlying 
mechanism(s) by which lymphocytes rescue neurons is not clear but it is proposed that T 
cells are capable of producing neurotrophic factors (Moalem et al., 2000) and inducing 
glutamate clearance by astrocytes (Garg et al., 2008) and microglia (Shaked et al., 2005) 
which may contribute to their neuroprotective role. 
 
Whether lymphocytes are detrimental or protective to the CNS may depend on the 
pathological conditions under which these cells infiltrate the CNS.  In the present study, we 
have utilised organotypic slice cultures (OSCs) to investigate how lymphocytes modulate cell 
death induced by either exposure to kainate (KA) or oxygen glucose deprivation (OGD).  
OSCs were utilised in the current study as they are used extensively as a model for 
investigating neurodegenerative diseases and to study mechanisms involved in 
neuroprotection (Wang et al., 2005; Cho et al., 2007) and importantly for the current study, 
OSCs maintain their inflammatory responses under our culture conditions (Huuskonen et al., 
2005).   We show that cell death induced by both toxic insults is reduced in the presence of 
lymphocytes and this protection is independent of the T cell activation state.  Furthermore, 
we demonstrate that this neuroprotection involves astrocytic activation via soluble mediators, 
with IL-16 being the lead candidate, and the inhibition of p38 mitogen activated protein 
kinase (MAPK) and extracellular signal-regulated kinases (ERK) signalling pathways.  These 
data indicate that under the current experimental conditions, lymphocytes are neuroprotective 
and suggest therapeutic opportunities which may prove useful in future interventions in 
pathological CNS conditions. 
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2. Materials and Methods 
2.1 Materials 
(2S,3S,4S)-3- (carboxymethyl)-4-(prop-1-en-2-yl)pyrrolidine-2-carboxylic acid (Kainic acid, 
KA), 2,3-dioxo-6-nitro-1,2,3,4-tetrahydrobenzo[f]quinoxaline-7- sulfonamide (NBQX), DL-
(-)-2-amino-5-phosphonopentanoic acid (DL-AP5), 4-[4-(4-Fluorophenyl)-2-[4-
(methylsulfinyl)phenyl]-1H-imidazol-5-yl] pyridine hydrochloride (SB203580), 1,4-
Diamino-2,3-dicyano-1,4-bis(2-aminophenylthio)butadiene (U0126) and 2-(4-Morpholinyl)-
8-phenyl-1(4H)-benzopyran-4-one (LY 294002) were obtained from Ascent Scientific, 
Bristol, UK. Sodium fluoroacetate (FA) was obtained from Sigma-Aldrich, Poole, UK. Anti-
phospho-p38 MAPK  and anti-phospho-c-Jun N-terminal kinase (JNK) antibodies were 
obtained from Invitrogen, Paisley, UK. Anti-phospho-ERK, total anti-p38 MAPK, total anti-
JNK and total anti-ERK antibodies were obtained from Santa Cruz Biotechnology, 
Heidelberg, Germany. All horseradish peroxidase (HRP)-conjugated secondary antibodies 
were purchased from Jackson Immuno- Research Laboratories, Newmarket, UK. Alexa Fluor 
anti-rabbit 488 and Alexa Fluor 555 anti-mouse, were obtained from Invitrogen (Paisley, 
UK). Anti-microtubule associated protein 2 (MAP2) was obtained from Sigma-Aldrich 
(Poole, UK) with anti-green fluorescent protein (GFP) obtained from Clontech (Mountain 
View, USA). 
 
2.2 Preparation of organotypic hippocampal slice cultures. 
Organotypic hippocampal slice cultures (OSCs) were prepared as described previously 
(Greenwood and Bushell, 2010).  Briefly, C57BL/6 mice (P4-7) were killed by cervical 
dislocation, according to Home Office UK Schedule 1 guidelines, followed by decapitation 
into ice-cold 70% ethanol. The brain was removed, transferred to ice-cold preparation media 
(50% MEM, 25% Hank balanced salt solution, 25% horse serum, 25 mM D-glucose and 1 
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mM L-glutamine), bisected and glued to a sterile dissecting platform.  Following submersion 
in ice-cold preparation media, parasaggital sections (300µm) were cut using a vibratome 
(Vibratome, Bannockburn, IL, USA) and the hippocampus removed. The slices were 
transferred to Millicel insert membranes (0.5 µm; Millipore Corporation, Bedford, MA, 
USA) and placed into 6-well culture plates containing pre-equilibrated preparation media (1 
mL/well). These were incubated at 370C / 5% CO2 for 24 hours after which the preparation 
media was replaced with serum-free culture media (SF media; 98% Neurobasal-A; 2% B27 
supplement and 2 mM L-glutamine) and maintained at 370C / 5% CO2. The culture media 
was then exchanged three times per week with all experiments performed on OSCs 
maintained for 13-15 days in vitro (DIV). 
 
2.3 Lymphocyte preparation. 
Peripheral lymph nodes were harvested from C57BL/6 mice (6-10 weeks old) and transferred 
to complete RPMI 1640 (cRPMI) media containing 10% foetal calf serum and 2mM L-
Glutamine.  The lymph nodes were homogenised and passed through a cell strainer (40 µm 
pore), transferred to a sterile tube and centrifuged at 400 x g for 5 minutes.   The pellet was 
then washed at least 2 times in serum free (SF) media and the cells re-suspended in SF media 
at 1 X 106 cells per ml, the final concentration used in all experiments.  T cells were purified 
from mixed lymphocyte preparations using magnetic cell sorting (pan T cell isolation kit; 
0LOWHQ\L %LRWHF 8. IROORZLQJ WKH PDQXIDFWXUHU¶V LQVWUXFWLRQV  For lymphocyte 
preparations containing GFP-expressing T cells used to investigate cell-cell interactions, 
these were isolated from hCD2-GFP transgenic mice (Fumagalli et al., 2011). In experiments 
where T cell activation was required, non-purified lymphocyte preparations were stimulated 
with anti-mouse CD3e (1µg /ml) for 24 hours whereas purified T cell preparations were 
exposed to both anti-mouse CD3e (2µg /ml) and anti-mouse CD28 (3µg /ml) for 24 hours. 
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2.4 Assessment of neuronal death using propidium iodide staining. 
OSCs (13-15 DIV) were checked under bright field microscopy for well-defined morphology 
prior to experimental use.. All drugs and lymphocytes (1 X 106 cells mL-1) were mixed in 
fresh culture media and equilibrated at 370C / 5% CO2. Conditioned media was prepared by 
centrifuging (2000 rpm, 10 minutes) media containing lymphocytes which were incubated for 
18 hours at 370C / 5% CO2 and where appropriate, drugs were added directly to conditioned 
media. For assessment of neuronal death, OSCs were transferred to culture media containing 
propidium iodide (PI; 2 µM) following exposure to KA for 1 hour and incubated for 18 hours 
at 370C / 5% CO2. For oxygen glucose deprivation experiments, artificial cerebro-spinal fluid 
(aCSF) containing (in mM): 124 NaCl, 3 KCl, 26 NaHCO3, 2.5 NaH2PO4, 2 MgSO4, 2 CaCl2 
and 10 sucrose was continuously bubbled with nitrogen for at least for 2 hours prior to OSCs 
being transferred to OGD-aCSF and incubated in a nitrogen chamber for 30 minutes with the 
OSCs then transferred into fresh PI containing media and incubated for 18 hours at 370C / 5% 
CO2. Where OSCs were incubated either with lymphocytes or conditioned media in the 
absence or presence of drugs, PI was added directly to the media and slices incubated for 18 
hours at 370C /5% CO2. Following treatment, OSCs were transferred to a microscope-
mounted incubator chamber (370C; Solent Scientific, Segensworth, UK) and PI fluorescent 
images were captured using a Nikon TE300 (Nikon, Kingston upon Thames, UK) inverted 
epi-fluorescent microscope (4X objective; Ex: 575/25 nm; Em: 626/28 nm) equipped with a 
Hamamatsu CCD camera (Hamamatsu Photonics, Welwyn Garden City, UK) controlled by 
Metamorph software (Molecular Devices Palo alto, CA, USA). The cell death was quantified 
by measuring the integrated density (mean fluorescence y slice area) of PI fluorescent images 
using ImageJ software (NIH) as described previously (Greenwood and Bushell, 2010).  A 
concentration-response curve was generated using KA (3 µM to 3 mM) to determine 
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neuronal death values were expressed throughout in terms of this maximum value.  In the 
OGD-induced cell death, a single treatment protocol was used. 
 
2.5 Cytokine array 
Commercially available cytokine antibody array dot blots (Proteome ProfilerTM Mouse 
Cytokine Array Panel A, R&D Systems Europe) were used to measure the relative amounts 
of cytokines in fresh media, media incubated for 18 h and lymphocyte-conditioned media. A 
detection antibody, each targeted to a specific cytokine, was added to the treated media 
samples. The cytokine antibody array dot blots were then incubated overnight at 4°C with the 
media. Following this, the media was washed from the blot and a Streptavidin-HRP solution 
was added to the membrane for 30 min at room temperature. The cytokine array dot blot was 
again washed and a chemiluminescent HRP substrate (Millipore) was added to the 
membrane. The dot blots were then imaged using the FujiFilm LAS-3000 imaging system. 
Images were captured as 8 bit grayscale TIFFs and the relative pixel density of each spot on 
the array was quantified using Image J software. 
 
2.6 Western blotting 
Western blotting was performed as previously described (Greenwood and Bushell, 2010).  
Briefly following treatment, OSCs were transferred to ice-cold HEPES-buffered saline and 
kept on ice. OSCs were washed three times with ice-cold phosphate buffer solution (PBS, 
2ml) and then cut out from the insert membranes and transferred to solubilisation buffer and 
incubated on ice for at least 1 hour with occasional vortexing. Insert membranes were 
removed and OSCs were triturated with a syringe and needle. Total cellular protein 
concentration was estimated by Bradford reaction and samples were normalised to 
0.444µg/µL by adding solubilisation buffer. Samples were further diluted by 25% by adding 
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sample buffer and boiled for 5 minutes to denature proteins. Samples were loaded in 10% 
SDS-polyacrylamide gels and subjected to electrophoresis which was blotted onto a 
nitrocellulose sheet. Non-specific binding was blocked by incubating blots with NaTT buffer 
containing 3% bovine serum albumin (BSA) for 2 hours. Blots were then incubated overnight 
with specific primary antibodies prepared in 0.2% BSA/NaTT then washed with NaTT buffer 
for 2 hours before incubating with either horse-radish peroxidase-conjugated anti-mouse or 
anti-rabbit IgG secondary antibody for 90 minutes.  Blots were again washed for 2 hours and 
developed using enhanced chemiluminescence (ECL) reagents with a X-OMAT developing 
machine. After detection of phosphor-specific bands, blots were stripped using a stripping 
solution for 1 hour on an orbital shaker. Blots were then washed for 30 minutes with NaTT 
buffer. These blots were then re-blocked and re-probed with non-phospho-specific antibody 
as described above.  
 
2.6 Immunohistochemistry 
OSCs were incubated with lymphocyte preparations containing GFP-expressing T cells for 
18 hours after treatment with or without KA for 1 hour. To confirm detection of GFP-
expressing T cells, 1 X 106 lymphocytes were added on the top of slices as opposed to the 
usual arrangement of T cells underneath the transwell membrane. After 18 hours, the media 
was removed by suction and 1 ml cold 4% paraformaldehyde (PFA) was added above and 
below the insert membrane for 5 minutes. OSCs were washed twice with cold PBS and 100% 
methanol was then added above and below the membrane for 10 minutes.  Following PBS 
washes, OSCs were incubated overnight with permeabilization solution (0.5% Triton X-100 
in PBS) before blocking with 20% Bovine serum albumin in PBS for 4 hours at room 
temperature. Anti-MAP2 (1:5000) and anti-GFP (1:400) antibodies were then applied in 5% 
BSA blocking solution to the OSCs overnight at 40 C. OSCs were then washed with blocking 
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solution and appropriate fluorescent secondary antibodies (Alexa488 and Alexa555) applied 
at room temperature (3 hours).  OSCs were then washed with 5% blocking solution and 
mounted, using Vectashield, on a glass microscope slide. Z stack images were captured using 
a Leica TCS SP-5 laser scanning confocal system with a 40x oil immersion lens and 
optimised using Adobe Photoshop (version 7.0). 
2.7 Data analysis 
All data are presented as mean ± S.E.M. with the number of slices indicated for all 
experiments performed on at least four different culture preparations. The differences 
between groups were analysed using a 6WXGHQW¶V unpaired t-test or one-way ANOVA with 
7XNH\¶V post-hoc analysis as appropriate. In all analyses, p< 0.05 were considered as 
significant. 
 - 12 - 
3. Results  
 
3.1 Lymphocytes are not toxic to OSCs. 
As it is unclear whether lymphocytes play either a protective or pathogenic role in the CNS, 
we first sought to determine whether lymphocytes were neurotoxic to OSCs under our 
experimental conditions.  Initially, OSCs were treated with a range of concentrations of KA 
(3 µM ± 3mM) for 1 hour before staining with propidium iodide (PI) to determine the 
maximum cell death.  As per previous studies in our laboratory (Greenwood and Bushell, 
2010), KA induces neurotoxicity in a concentration-dependent manner with maximum cell 
death observed at 3mM (Figure 1A & B).  Hence in all further experiments, OSCs were 
treated with KA (300 µM, 60 min) as a positive control of neurotoxicity with all levels of cell 
death being expressed as a percentage of this 3mM KA maximum. This toxicity was 
completely abolished in the presence of both the AMPA/KA antagonist, NBQX (20 µM), and 
the NMDA antagonist, DL-AP5 (100 µM; QSFRPSDUHGWR.$ (300 µM) alone; 
Figure 1C). In contrast to the effects of KA, mixed lymphocyte preparations did not induce 
neurotoxicity in OSCs when exposed to lymphocytes for up to 18hours (P>0.05 compared to 
control, Figure 1A & C). This lack of neurotoxicity was evident irrespective of T cell 
activation, since OSCs exposed to T cells in the presence (18h, n=17) or absence (18h, n=9) 
of anti-CD3e stimulation displayed no evidence of cell death (Figure 1C). Together, these 
data demonstrate that lymphocytes are not directly neurotoxic to OSC in our mixed cell 
culture system. 
 
3.2 Lymphocyte preparations exhibit neuroprotection against KA-induced cell death. 
Having established that lymphocyte preparations are not neurotoxic to OSCs, we investigated 
whether OSC exposure to lymphocytes modulates KA-induced excitotoxicity. The presence 
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of lymphocytes for only 1 hour during initial treatment with KA (300 PM, 1h) resulted in 
similar levels of OSC toxicity as KA alone and this was independent of T cell activation state 
(non-activated T cells, n=16, P>0.05 compare to KA alone; activated T cells, n=14, P>0.05 
compare to KA alone, Figure 2B).  In contrast, significant neuroprotection was observed 
when OSCs were co-cultured with lymphocytes for 18hours following an initial exposure to 
KA (300 PM, 1h).  This lymphocyte-mediated neuroprotection was independent of T cell 
activation as KA-induced toxicity was reduced from 67.5 ± 5.6% (n=30) to 50.8 ± 3.8% 
(n=48, P<0.05 compared to 300 PM KA alone, Figure 2A & B) and 45.4 ± 3.4% (n=50, 
P<0.01 compared to 300 PM KA alone, Figure 2A & B) for preparations containing non-
activated and activated T cells respectively. Thus, in our model of KA-induced excitotoxicity, 
lymphocytes are able to exhibit neuroprotection and this is independent of T cell activation. 
 
3.3 Purified T cells exhibit neuroprotection against KA-induced cell death. 
Having determined that a mixed lymphocyte population is neuroprotective in our 
experimental system, we next sought to determine the cell type responsible for mediating 
protection. Using flow cytometry, we confirmed that approximately 70% of the cells in our 
lymphocyte preparations were T cells (68.5 ± 1.8 %, n = 16). Therefore, to investigate the 
role of T cells in the observed protection against KA-induced neuronal death, T cells were 
purified from mixed lymphocyte preparations. In agreement with our initial findings, mixed 
lymphocyte preparations significantly reduced cell death in OSCs from 66.8 ± 2.7% (n=10) 
to 31.6 ± 3.1% (n=8, P<0.001 compared to 300 PM KA alone, Figure 2C).  Similarly, T cells 
purified from the same lymphocyte preparation significantly reduced KA-induced neuronal 
death, an effect that was independent of T cell activation state with cell death being reduced 
to 42.7 ± 2.9% (n=9, P<0.001 compared to 300 PM KA alone, Figure 2C) and 51.7 ± 5.8% 
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(n=6, P<0.05 compared to 300 PM KA alone, Figure 2C) for non-activated and activated 
purified T cells respectively. 
 
3.4 Soluble mediators underlie lymphocyte-induced neuroprotection. 
Having established that lymphocyte preparations and purified T cells are neuroprotective 
under our experimental conditions, we investigated the mechanisms underlying the observed 
neuroprotection.  To determine whether soluble mediators underlie lymphocyte-mediated 
neuroprotection, lymphocyte conditioned media (LCM) was assessed for protection against 
KA-induced neurotoxicity.  Lymphocytes were cultured for 18 hours alone or in the presence 
of OSCs and the purified conditioned media transferred to KA-treated OSCs. Cell death in 
OSCs maintained in LCM for 18 hours after initial exposure to KA was significantly reduced 
irrespective of whether LCM was purified from mixed cultures of lymphocytes and OSC or 
from lymphocytes alone, suggesting that soluble mediators are responsible for the 
neuroprotective effects and that these are solely produced by lymphocytes (Figure 3A & B).  
In contrast, the neuroprotective effect of LCM was abolished when the media was boiled 
(63.4 ± 4.8%, n=7, P>0.05 compared to 300 PM KA alone, Figure 3A & B), suggesting the 
neuroprotective factor in LCM is protein in nature.  Furthermore, to confirm that 
lymphocytes were essential for the LCM-mediated neuroprotection, conditioned media (CM) 
taken from KA treated slices (61.8 ± 3.8%, n=9, P>0.05 compared to 300 PM KA alone) and 
CM from primary hippocampal cultures (61.1 ± 3.6%, n=10, P>0.05 compared to 300 PM 
KA alone) were ineffective against KA-induced neurotoxicity.  Further confirmation that 
direct cell-cell interaction is not required for the observed neuroprotection was achieved by 
utilising lymphocyte preparations containing GFP-expressing T cells isolated from hCD2-
GFP transgenic mice in order that any T cell infiltration of the OSCs could be easily 
visualised.  Examination of slices, either with or without the exposure of KA, maintained for 
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18 hours in the presence of lymphocyte preparations containing GFP-expressing T cells under 
conditions identical to those described above, revealed no infiltration of T cells into the OSCs 
although GFP-expressing T cells were observed when applied directly to the slice (data not 
shown).  These data strongly suggest that soluble mediators released from lymphocytes are 
responsible for the observed neuroprotection, with no cell-cell interaction required. In order 
to try and identify the soluble mediator(s) involved, arrays were performed to analyse the 
levels of 40 cytokines found in fresh media, media incubated for 18 hours and LCM that was 
prepared as per the neuroprotective experiments described earlier.  These cytokine arrays 
revealed that a robust increase in IL-16 levels were evident in LCM compared to fresh and 
incubated media (Figure 3C & D) with the level of all other cytokines investigated being 
similar in all three media preparations indicating that IL-16 may be the soluble mediator 
underlying the neuroprotective effects observed in the current experiments.  
 
3.5 Lymphocyte mediated neuroprotection involves astrocytic activation and inhibition 
of ERK and p38 MAP kinase signalling. 
Despite having identified IL-16 as the potential cytokine underlying the lymphocyte-
mediated neuroprotection, the cell type and signalling pathways within the OSCs on which it 
acts to produce this effect is unknown.  Hence we next utilised the glial metabolic inhibitor, 
fluoroacetate (FAc), which we have successfully used to investigate astrocyte function in 
previous studies (Greenwood and Bushell, 2010; Gan et al., 2011).  Exposure of OSCs to 
FAc (10 PM, 3h) did not affect KA-induced cell death (n=12, P>0.05 compared to 300 PM 
KA alone, Figure 4A). However, neuroprotection elicited by LCM (50.7 ± 5.2%, n=15, 
P<0.01 compared to 300 PM KA alone) was significantly reduced in FAc-treated OSCs (66.2 
± 2.8%, n=10, P<0.001 compared to 300 PM KA + LCM, Figure 4A), suggesting that 
astrocytes are important in the neuroprotection induced by lymphocytes. We then examined 
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whether common signalling pathways that are known to be modulated by numerous 
immunological mediators, namely MAPKs, are involved in the lymphocyte-mediated 
neuroprotection.  Initial experiments were performed to determine if and how MAPK activity 
was modulated following KA-induced cell death in the absence and presence of lymphocytes.  
However, exposure of OSCs to KA led to considerable variability in the MAPK activity 
between slices and experiments and thus we decided to determine the effect on MAPK 
activity of subjecting untreated OSCs to lymphocytes.  Exposure of OSCs to lymphocytes 
(18h) resulted in a significant reduction in ERK and p38 MAPK activity to 66.2 ± 6.1 % of 
control (n=10, P<0.05 compared to control, Figure 4B & C) and 64.1 ± 4.5% of control (n=6, 
P<0.05 compared to control, Figure 4B & C). In contrast, JNK 1/2 activity was unaffected by 
exposure to lymphocytes (108.6 ± 12.7% of control, n=10, P>0.05 compared to control, 
Figure 4B & C).  If this lymphocyte-mediated reduction in ERK and p38 MAPK activity in 
untreated slices contributed to the observed lymphocyte-mediated neuroprotection against 
KA-induced cell death, the pharmacological inhibition of both kinases should also be 
protective against KA-induced neurotoxicity.  Indeed, co-incubation with the p38 MAPK 
inhibitor, SB203580 (100PM), and the upstream ERK inhibitor, U0126 (20PM) significantly 
reduced KA-induced cell death from 71.8 ± 2.8 (n=15) to 53.1 ± 1.1 (n=11, P<0.001 
compared to 300 PM KA, Figure 4D).  Having shown a role for MAPK inhibition, we also 
investigated whether the PI3K pathway is involved in lymphocyte-mediated neuroprotection.  
To negate any issues regarding PI3K inhibition on lymphocyte function, pharmacological 
inhibition of PI3K using LY294002 (10PM) was performed in the presence of lymphocyte 
conditioned media (LCM).  LCM significantly reduced KA-induced cell death from 71.8 ± 
2.8 (n=15) to 53.3 ± 2.0 (n=11, P<0.01 compared to 300 PM KA, Figure 4D) and this was 
unaffected by treatment with LY294002 (56.6 ± 2.2%, n=13, P>0.05 compared to 300 PM 
KA + LCM, Figure 4D).  In the absence of LCM, no change in KA-induced toxicity was 
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observed in the presence of LY294002 (68.7 ± 1.6%, n=6, P>0.05 compared to KA alone, 
Figure 4D). 
   
3.6 Lymphocytes are protective against OGD-induced toxicity.  
Having established the neuroprotective effect of lymphocytes against KA-induced toxicity, 
we further investigated whether lymphocytes protect OSCs against another in vitro model of 
neurotoxicity, OGD.  OGD (30 mins) induced significant cell death in OSCs and exposure to 
lymphocytes reduced the neurotoxicity to 61.6 ± 3.0 % of OGD control (n=19, P<0.001 
compared to control, Figure 5A & B).  LCM also significantly reduced OGD-induced cell 
death to 65.9 ± 7.4 % of OGD control (n=5, P<0.05 compared to control, Figure 5B) 
indicating that in agreement with the KA-induced toxicity experiments, soluble mediators 
released by lymphocytes are responsible for the observed neuroprotection against OGD.  
However, in contrast to the KA experiments, pre-treatment of OSCs with FAc (10PM, 3hr) 
had no significant effect LCM-mediated neuroprotection (56.8 ± 6.0 % of OGD control, n=6, 
P>0.05 compared to LCM alone, Figure 5B), a finding which suggests that astrocytes do not 
play a significant role in the protection against OGD.   However, similar signalling 
mechanisms appear to underlie the observed neuroprotection as co-incubation with 
SB203580 (100PM), and U0126 (20PM) significantly reduced OGD-induced toxicity to 66.3 
± 5.9 % of control (n=9, P<0.01 compared to OGD control, Figure 5B) whereas LY294002 
(10PM) was without effect (72.5 ± 1.6% of OGD control, n=6, P>0.05 compared to LCM 
alone, Figure 5B). 
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4. Discussion  
In the present study, we show that lymphocytes are protective in two in vitro models of 
neurotoxicity and that protection is independent of T cell activation.  We suggest that the 
lymphocyte-mediated protection involves soluble mediators, presumably IL-16 and, at least 
in the case of KA-induced toxicity, is mediated indirectly via astrocytes. In addition, we 
propose that an inhibition of both p38 MAPK and ERK activity contributes to the observed 
neuroprotection. 
 
4.1 Lymphocytes are neuroprotective independent of T cell activation state. 
The role of the immune system in modulating the CNS under physiological and 
pathophysiological conditions is an area of intense interest.  Classically, activation of the 
immune system and recruitment of immune cells was thought to contribute to and exacerbate 
pathophysiological conditions within the CNS.  Indeed, in the archetypal autoimmune CNS 
disease, multiple sclerosis, it is established that lymphocytes invade the CNS and contribute 
to the disease neuropathology (Larochelle et al., 2011; Stadelmann, 2011) and a role for 
QHXURLQIODPPDWLRQ KDV EHHQ LPSOLFDWHG LQ QXPHURXV &16 GLVHDVHV LQFOXGLQJ $O]KHLPHU¶V
disease *UDPPDV  DQG 3DUNLQVRQ¶V GLVHDVH %DUQXP DQG 7DQVH\  4LDQ HW DO
2010) .  However, studies also suggest that lymphocytes may have a neuroprotective role in 
the CNS when investigated using models of spinal cord injury (Yoles et al., 2001; Sroga et 
al., 2003; Beck et al., 2010), facial nerve axotomy (Serpe et al., 1999; Sanders and Jones, 
2006; Xin et al., 2011) and ischaemia (Frenkel et al., 2005; Liesz et al., 2009).  This latter 
role for lymphocytes reflects our finding in the present study that lymphocytes are not 
neurotoxic to OSCs under our experimental conditions but are protective against KA-induced 
and OGD-induced toxicity.  Our findings are in agreement with a previous study which 
focused specifically on the consequence of exposing organotypic cultures to T cell subtypes 
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(Wolf et al., 2002).  It revealed that both Th1 and Th2 cells were protective in a contact 
independent manner.  However in contrast to our own study, increased neuroprotection was 
observed following T cell activation and protection was against secondary damage initiated 
by explantation of tissue from living animal to the culture dish. Conversely, our study utilised 
established models of neurodegeneration and experimental ischaemia to assess lymphocyte-
mediated neuroprotection (Noraberg et al., 2005; Wang et al., 2005; Zheng et al., 2011).  
Hence we have shown for the first time that lymphocytes are protective in established in vitro 
models of neurodegeneration and ischaemia.  Furthermore, in our hands, this neuroprotection 
is independent of the T cell activation state with lymphocyte-mediated neuroprotection being 
similar whether or not they contained activated T cells.  This was also true when purified T 
cells were utilised, with both activated and non-activated purified T cells being protective 
against KA-induced neurotoxicity. The discrepancy in the role of T cell activation state 
between our studies could simply be due to the experimental parameters used to investigate T 
cell function, but further investigation into this is beyond the scope of this study.  
 
 As stated previously, the finding that T cells were neuroprotective is in agreement with 
previous studies where T cell function has been investigated in in vivo models of 
neurodegeneration (Serpe et al., 1999; Yoles et al., 2001; Sroga et al., 2003; Frenkel et al., 
2005; Sanders and Jones, 2006; Liesz et al., 2009; Beck et al., 2010; Xin et al., 2011).  
However, it should be noted that many of these studies were performed in immune 
compromised animals and as such, it could be argued that the observed effects may be due to 
T cell independent broader effects of development in the absence of a functioning adaptive 
immune system (Rook et al., 2011).  With regard to T cell subtypes and neuroprotection, 
recent studies have implicated Treg cells as being the key lymphocyte population involved in 
neuroprotection in experimental stoke (Liesz et al., 2009 but also see Ren et al., 2011). 
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Similarly, in experimental autoimmune encephalitis (EAE) models, neurons have been 
proposed to induce Treg cells from encephalitogenic T cells and these Treg cells function to 
supress EAE (Liu et al., 2006).  In addition to Treg, Th2 cells have been suggested to play a 
role in neuroprotection (Hendrix and Nitsch, 2007; Yong and Marks, 2010) but there are 
discrepancies as to whether this occurs in a contact-dependent (Roy et al., 2007) or contact-
independent manner (Wolf et al., 2002).  Our findings support the suggestion that T cells can 
be neuroprotective and that protection is via soluble factors; however which T cell subtype is 
responsible for these effects under our experimental conditions requires further investigation. 
 
4.2 Lymphocyte-mediated neuroprotection is contact-independent. 
Having established that lymphocyte preparations are neuroprotective in a contact-
independent manner, we also sought to identify the underlying mechanisms.  We confirmed 
that soluble mediators were responsible for the observed neuroprotection as lymphocyte-
conditioned media was protective against KA-induced and OGD-induced toxicity.  
Furthermore, as boiling the lymphocyte-conditioned media abolished this neuroprotection, 
we conclude that protein(s) within the media underlie this neuroprotection.  We performed an 
array of 40 cytokines in order to try and identify the cytokine(s) potentially underlying this 
neuroprotection with our results revealing a robust increase in IL-16 levels only in media 
conditioned in the presence of lymphocytes with all other cytokines investigated being at 
similar levels in all three conditions examined.  IL-16 was originally described as a T cell 
chemoattractant factor but it is now accepted as a cytokine as it lacks the classic chemokine  
motifs (Center and Cruickshank, 1982; Cruickshank and Center, 1982; Bacon et al., 2002). In 
T cells, IL-16 has been shown increase intracellular Ca2+, inositol 1,4,5-triphosphate levels 
and stress activated protein kinase activity as well as stimulate the release of proinflammatory 
cytokines (Cruickshank et al., 1991; Krautwald, 1998; Zhang et al., 2008); whether IL-16 
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elicits similar changes in CNS cell types remains unknown.  However, a neuronal IL-16 has 
also been described and it is proposed that this neuronal form may play some autocrine 
function within the CNS (Kurschner and Yuzaki, 1999) by interacting with CD4 which has 
been shown to be expressed in neurons (Omri et al., 1994).  Regarding the role of IL-16 in 
CNS diseases, evidence exists relating increased levels of IL-16 to disease severity in the 
EAE mouse model (Skundric et al., 2005) and increased microglial expression following 
trimethyltin neurotoxicity (Guo et al., 2004) indicating that elevated IL-16 levels are linked to 
detrimental events.  In contrast to this, recent evidence suggests that IL-16 may play a 
neuroprotective role by interacting with its binding partner, CD4 and its co-receptor CCR5 as 
these have been shown to be expressed in several cell types within the CNS (Omri et al., 
1994, Sorce et al., 2011). Indeed, CCR5 has been shown to be upregulated by a number of 
neurotoxic insults including kainic acid (Chen et al., 2003).  Furthermore, motor neuron death 
is accelerated in the absence of CCR5 (Gamo et al., 2008) and CCR5 deficient mice have 
reduced infarct size indicating a protective role of this receptor (Sorce et al., 2010) but 
whether this is mediated via glia cells or a direct action on neurons is unknown.  Therefore it 
remains speculation as to whether the neuroprotection observed in the present study is 
mediated via IL-16 acting directly on cells within the OSC or via stimulating the release of 
other factors from lymphocytes not detected in our array but our data indicates that the 
neuroprotective effects revealed in this study involves IL-16 but the exact mechanisms 
require further investigation.   
 
4.3 Neuroprotection requires astrocytic activation and MAPK inhibition. 
Having identified a potential specific soluble mediator that underlies the lymphocyte-
mediated neuroprotection under our experimental conditions, we then chose to determine 
whether they interacted with a specific cell type within OSCs to induce the neuroprotection.  
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OSCs are made up of a heterologous population of cell types including astrocytes, microglia 
and neurons. Hence, due to the recent increase in our understanding of astrocytes function 
within the CNS under both physiological and pathophysiological conditions (Bélanger and 
Magistretti, 2009; Rodriguez and Verkhratsky, 2011) and having established that astrocytes 
were involved in the neuroprotection observed against KA-induced neurotoxicity in OSCs in 
a previous study (Greenwood and Bushell, 2010), we investigated whether inhibition of 
astrocytic activity would alter the lymphocyte-mediated neuroprotection using techniques 
established in our laboratory (Greenwood and Bushell, 2010; Gan et al., 2011).  Inhibition of 
astrocytic activity using the glial toxin, FAc, abolishes lymphocyte-mediated neuroprotection 
against KA-induced neurotoxicity but not in the OGD model.  Until recently, the primary role 
of astrocytes in the normal brain was thought to be maintaining the microenvironment of 
neurons by performing roles including glutamate uptake and recycling, pH and K+ buffering 
as well as supply of energy substrates (Bélanger and Magistretti, 2009; Rodriguez and 
Verkhratsky, 2011) whereas it is now proposed that astrocytes can play a key role in 
modulating synaptic transmission and plasticity (Bélanger and Magistretti, 2009; Perea et al., 
2009; Barker and Ullian, 2010; Rodriguez and Verkhratsky, 2011). Furthermore, astrocytes 
have recently come under scrutiny regarding their role in neurodegeneration associated with 
FHUWDLQ&16GLVRUGHUVLQFOXGLQJ$O]KHLPHU¶VGLVHDVHDQG3DUNLQVRQ¶VGLVHDVe (Bélanger and 
Magistretti, 2009; Halliday and Stevens, 2011; Rodriguez and Verkhratsky, 2011).  However, 
there is debate as to whether astrocytes are either beneficial or detrimental in CNS diseases 
and this may depend on how far the disease has progressed and / or on which mediators are 
released at that stage of the disease.  Astrocytes are capable of releasing anti- and / or pro-
inflammatory mediators and it may depend on the relative relationship of these which 
determines the eventual contribution of astrocytes to the disease.  Under our experimental 
conditions, astrocytes clearly play a role in the observed neuroprotection against KA-induced 
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toxicity as shown by the loss of neuroprotection when astrocytic function is inhibited using 
FAc.  The ability of astrocytes to release neurotrophins is thought to contribute to their role in 
neuroprotection with for example, BDNF and glial derived neurotrophic factor (GDNF) 
known to be neuroprotective in models of neurodegenerative disorders for many years (Spina 
et al.,1992; Tomac et al., 1995). Indeed, GDNF has been the subject of intense investigation 
LQUHFHQWWLPHVUHJDUGLQJLWVSRWHQWLDOWKHUDSHXWLFXVHLQ3DUNLQVRQ¶VGLVHDVH (Mickiewicz et 
al., 2011; Safi et al., 2011).  However, whether astrocytically released neurotrophins do 
indeed underlie the lymphocyte-mediated neuroprotection in the present study requires 
further investigation especially as it has been suggested that T cell induced release of 
neurotrophins from astrocytes is contact-dependent (Roy et al., 2007).  In contrast to the role 
astrocytes play in lymphocyte-mediated neuroprotection against KA-induced toxicity, our 
data indicates that astrocytes do not contribute to lymphocyte-mediated protection against 
OGD-induced toxicity. The sensitivity of astrocytes to ischaemic insults has long been an 
area of debate with astrocytes from different brain regions showing differential sensitivity to 
ischaemia and in vitro models of ischaemia revealing that despite both astrocytes and neurons 
being sensitive to OGD, astrocytic death is delayed in comparison to neuronal death (Zhao 
and Flavin, 2000; Xu et al., 2001; Giffard and Swanson, 2005; Ouyang et al., 2007).  In 
contrast, astrocytic dysfunction is proposed to contribute to ischaemia-induced loss of 
neurons in in vivo models of forebrain ischaemia (Chen et al., 2005; Giffard and Swanson, 
2005).  This divergence in the role of astrocytes may indicate that OGD toxicity is not cell 
type selective whereas KA induces toxicity primarily in neurons and therefore astrocytes do 
not contribute to the neuroprotection against OGD because they themselves are dysfunctional 
or dead.   Despite this, it is clear that lymphocytes are protective in two different in vitro 
neurodegenerative models and the soluble mediators involved may have direct actions 
resulting in neuroprotection either directly or indirectly via astrocytes. 
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Having shown that lymphocytes were neuroprotective in two different in vitro 
neurodegenerative models, we sought to investigate the signalling pathways that may 
underlie this.  We focussed our efforts on the MAPK and PI3K pathways as it is well 
established that cytokines can modulate both these pathways (Schieven, 2009; Kim and Choi, 
2010; Kim and Suresh, 2013) and that modulators of the MAPK pathway in particular are 
therapeutic targets for the CNS neurodegenerative disorders (Cuny, 2009; Yasuda et al., 
2011). Exposure of OSCs to lymphocytes reduced p38 MAPK and ERK activity whereas no 
effect on JNK 1/2 activity was observed.  Significantly, when the reduction in MAPK activity 
was mimicked using pharmacological inhibitors, a similar level of    neuroprotection was 
observed.   As the lymphocyte-mediated neuroprotection is contact-independent, these data 
indicate that the soluble mediators released by lymphocytes results in this reduction in 
MAPK activity.  Of the potential candidates, this reduction in activity would suggest that 
neurotrophins do not underlie the protection as studies have shown they generally lead to the 
activation of MAPK pathways via Trk receptors (Ouwens et al., 2002; Shi et al., 2005; 
Reichardt, 2006).  Despite this, it is interesting to note that the neuroprotection mediated by 
lymphocytes involves an inhibition of p38 MAPK as increased p38 MAPK activity has been 
associated with several CNS neurodegenerative disorders and inhibitors of its activity are 
proposed as therapeutic drugs for CNS disorders (Cuny, 2009; Yasuda et al., 2011).  In 
contrast to the role of p38 MAPK in neurodegeneration, it is generally thought that ERK 
activation is neuroprotective (Mehta et al., 2007) however there is a growing body of 
evidence which suggests that increased and /or prolonged ERK activation may indeed 
contribute to cell death and CNS diseases (Zhuang and Schnellmann, 2006).  Hence it is 
feasible that a reduction in ERK activity as observed in the present study would be 
advantageous in terms of cell survival.  Finally, our finding that JNK 1/2 activity is 
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unaffected by exposure to lymphocytes suggests that modulation of this pathway does not 
appear to contribute to the observed lymphocyte mediated neuroprotection. 
 
5. Conclusions 
In conclusion, our data demonstrates that lymphocytes are neuroprotective against KA-
induced and OGD-induced toxicity under our experimental conditions and that this is 
independent of T cell activation.  We propose that this neuroprotection is mediated indirectly 
by the action of a soluble mediator, likely to be IL-16, on astrocytes and the inhibition of 
ERK and p38 MAPK activities.  These data, along with previous studies, suggest a 
neuroprotective role for lymphocytes in models of neuronal death or injury, and that 
lymphocytes may play multiple roles in CNS disorders. However, further investigation is 
required to decipher when and why the divergence between their proposed protective or 
detrimental roles occur in vivo.  
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Figure Legends 
Fig 1.  Lymphocytes do not induce neurotoxicity in organotypic slice cultures. A. 
Representative images showing propidium iodide fluorescence 18h after exposure to KA (30 
µM and 300 µM, 1 h) or mixed lymphocytes (1h).  B. KA induces neuronal cell death in 
OSCs in a concentration-dependent manner. C. Summary illustrating the effects of 
lymphocyte preparations containing activated and non-activated T cells on neuronal survival 
in OSCs.  Data are expressed as mean ± S.E.M. and are normalised with respect to 3mM KA. 
***P<0.001 versus control.  Scale bars: 150 µm. 
 
Fig 2. Lymphocyte-mediated neuroprotection against KA-induced neurotoxicity is 
independent of T cell activation state.  A. Representative images illustrating cell death 18h 
after exposure to KA alone (300 µM, 1h) or KA followed by exposure to lymphocytes 
containing activated or non-activated T cells (18h).  B. Bar chart revealing that lymphocyte 
preparations were ineffective against KA-induced neurotoxicity when OSCs were exposed to 
lymphocytes for 1h post insult whereas neurotoxicty was significantly reduced in OSCs 
exposed to lymphocytes for 18 h post insult with this protection being independent of T cell 
activation state.  C. Summary showing that protection against KA-induced neurotoxicity is 
observed with purified T cells, independent of activation state and T cell depleted lymphocyte 
preparations.  Data are expressed as mean ± S.E.M. and are normalised with respect to 3mM 
KA. *P<0.05, **P<0.01, ***P<0.001 versus control.  Scale bars: 150 µm. 
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Fig 3. Soluble mediators underlie lymphocyte-mediated neuroprotection. A. 
Representative images illustrating cell death 18 h after exposure to KA alone (300 µM, 1h) 
and in the presence of lymphocyte conditioned media (LCM) or boiled LCM for 18h post 
insult.  B. Summary illustrating that LCM is neuroprotective against KA-induced toxicity and 
the conditioning is not dependent on the presence of OSCs.  In contrast, boiled LCM or 
conditioned media (CM) from KA treated OSCS or primary hippocampal cultures are without 
effect.  C.  Representative array blot for IL-16 revealing a robust increase in IL-16 in LCM 
compared to media controls. D. Scatter plot showing IL-16 values from the primary screening 
of 40 cytokines. No difference was seen in the other 39 cytokines assayed.  Data are 
expressed as mean ± S.E.M. and are normalised with respect to 3mM KA. **P<0.01 versus 
control. ###P<0.001 versus KA + LCM.  Scale bars: 150 µm. 
 
Fig 4. Astrocytic activation and inhibition of MAPK activity underlies lymphocyte-
mediated neuroprotection.  A. The glial toxin, FAc (10 µM) does not reduce KA-induced 
toxicity but abolishes LCM-mediated neuroprotection.  B. Representative blots illustrating 
that exposure to lymphocytes  reduces p-p38 MAPK and p-ERK but not total protein in  
OSCs.  No effect on p-JNK 1/2 or total JNK was observed.  C. Bar chart revealing the effect 
of lymphocytes on p38 MAPK, ERK and JNK 1/2 activity in OSCs.  D. Summary illustrating 
that the pharmacological inhibition of p38 MAPK and ERK with SB203580 and U0126 is 
neuroprotective against KA-induced neurotoxicity whereas inhibition of PI3K was without 
effect on LCM-mediated neuroprotection.  Data are expressed as mean ± S.E.M.  and are 
normalised with respect to 3mM KA. *P<0.05, **P<0.01, ***P<0.001 versus control, 
###P<0.001 versus LCM alone.  Scale bars: 150 µm. 
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Fig 5. Lymphocytes are neuroprotective against OGD-induced cell death.  
A. Representative images illustrating cell death in OSCs 18 h after exposure to OGD (30 
mins) either alone or maintained in the presence of lymphocytes.  B.  Summary showing that 
lymphocytes and LCM are protective against OGD-induced cell death, an effect which is 
mimicked by p38 MAPK and ERK inhibition but not by PI3K inhibition.  Data are expressed 
as mean ± S.E.M.  and are normalised with respect to 3mM KA. *P<0.05, **P<0.01, 
***P<0.001 versus control.  Scale bars: 150 µm. 
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